Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 680 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Vaccine 2 Clear all
Completed Phase 1 Interventional

Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

NCT00426712
View directory record Official record
Conditions
Hepatitis B
Interventions
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
40 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Costa Mesa, California • Brooklyn Center, Minnesota • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 16, 2026, 8:08 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

NCT00350337
View directory record Official record
Conditions
Dengue
Interventions
Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

State Immunization Information Systems to Improve HPV Vaccination Rates

NCT02993965
View directory record Official record
Conditions
Vaccine, Human Papiloma Virus Vaccine, HPV Vaccine, Immunization, Health Registry, Adolescent Health, Reproductive Health, Preventive Health Services
Interventions
Vaccine Reminder/Recall
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
11 Years to 17 Years
Enrollment
77,716 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Traveler's Diarrhea (TD) Automated Process

NCT00751777
View directory record Official record
Conditions
Prevention of Travelers' Diarrhea
Interventions
heat-labile enterotoxin of E. coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Vallejo, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The STOP-HPV Trial 1: Communication Intervention

NCT03599557
View directory record Official record
Conditions
Immunization, Vaccination
Interventions
STOP-HPV communication intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Itasca, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Not applicable Interventional Results available

Does Framing and Humor Improve the Effectiveness of Messages About COVID-19 Vaccine

NCT05085613
View directory record Official record
Conditions
Beliefs
Interventions
Corrective message framing and humor
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
21 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 16, 2026, 8:08 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

NCT07226882
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 44 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
6
States / cities
Warren Township, New Jersey • Cortland, New York • Horseheads, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 16, 2026, 8:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effective Analgesia During Routine Immunizations

NCT01368861
View directory record Official record
Conditions
Pain
Interventions
Not listed
Lead sponsor
Children's Hospital of The King's Daughters
Other
Eligibility
2 Months to 4 Months
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H7N9 Mix and Match With MF59 in Healthy Adults

NCT01938742
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 64 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
4
States / cities
Decatur, Georgia • Iowa City, Iowa • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT04854746
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-GI.1.NN, Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cypress, California • New Orleans, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

NCT05298254
View directory record Official record
Conditions
Herpes Simplex
Interventions
Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3, HSV formulation 1 with adjuvant 1, HSV formulation 2 with adjuvant 1, HSV formulation 3 with adjuvant 1, HSV formulation 1 with adjuvant 2, HSV formulation 2 with adjuvant 2, HSV formulation 3 with adjuvant 2, Placebo, HSVTI_F1, HSVTI_F2
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

NCT01373294
View directory record Official record
Conditions
Bladder Cancer
Interventions
Bacille Calmette-Guerrin (BCG), Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 16, 2026, 8:08 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

NCT02768363
View directory record Official record
Conditions
Prostate Cancer
Interventions
aglatimagene besadenovec, placebo, valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Golden, Colorado • Chicago, Illinois • New Orleans, Louisiana + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

NCT01857206
View directory record Official record
Conditions
Influenza, Fever
Interventions
Mammalian cell based flu vaccine, Egg based flu vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
4 Years to 17 Years
Enrollment
2,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
18
States / cities
Mobile, Alabama • Ponte Vedra, Florida • Augusta, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 16, 2026, 8:08 PM EDT
Terminated Phase 2 Interventional Results available

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

NCT04684914
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
HepTcell, Placebo
Biological · Drug
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Garden Grove, California • Redwood City, California • San Jose, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly

NCT00347555
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study

NCT01908517
View directory record Official record
Conditions
Patient Compliance
Interventions
HPV Vaccine Electronic Reminders
Behavioral
Lead sponsor
East Carolina University
Other
Eligibility
9 Years to 17 Years
Enrollment
522 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Greenville, North Carolina • Snow Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Inactivated Influenza A/H5N1 Vaccine in the Elderly

NCT00230750
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Torrance, California • Rochester, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 16, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

NCT03981952
View directory record Official record
Conditions
Risk Reduction
Interventions
Trivalent Invasive Salmonella Disease Vaccine (6.25 µg), Trivalent Invasive Salmonella Disease Vaccine (12 µg), Trivalent Invasive Salmonella Disease Vaccine (25 µg), Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C), Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 16, 2026, 8:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Engaging College Students in Developing and Testing a Video-based Intervention for HPV Vaccination Promotion

NCT06397378
View directory record Official record
Conditions
N/A - Healthy Subjects
Interventions
short videos related to HPV and the HPV vaccine, CDC HPV Fact Sheet
Other
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 26 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 16, 2026, 8:08 PM EDT